Open access
Oct 2026
Effectiveness of Newly Initiated Tofacitinib and Biologic DMARDs in Patients with Rheumatoid Arthritis.
There were no statistically significant differences in CDAI remission and LDA rates between treatments at 6 and 12 months and potential HTE was observed among subgroups of age ≥ 50 years, obesity, prior b/tsDMARD use, corticosteroid use, and Sjӧgren's disease.
K. Liao, C. Gopalakrishnan, J. Yazdany et al.
· Rheumatology and Therapy · 0 citations